Yeast two-hybrid screening was used to explore novel proteins that interact with a breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase). The screening yielded NHERF (Na + /H + exchanger regulatory factor, also known as NHERF1 or EBP-50) that binds to the interdomain B of SYK. NHERF is an estrogen-responsive gene that encodes an inhibitory factor for epithelial Na + /H + exchanger isoform 3 (NHE3). We found intragenic mutation of the NHERF gene accompanied by loss of heterzygosity (LOH) in B3% (3/85) of breast cancer cell lines and primary breast tumors. Mutations occurred at the conserved PDZ domains at NHERF NH 2 -terminus that bound to SYK, or at its COOH-terminus motif that binds to MERLIN, the product of Neurofibromatosis 2 (NF2) tumor suppressor gene. NHERF tumorigenic mutations decreased or abolished its interaction with SYK or MERLIN, suggesting a pathway link among these three molecules that may play a critical role in mammary neoplastic progression. Primary breast tumors with LOH at the NHERF locus had clinical presentations of higher aggressiveness, indicating that deregulated NHERF signaling may be associated with disease progression. Moreover, the LOH was inversely correlated with SYK promoter methylation, suggesting that NHERF and SYK may transduce a common suppressive signal. Taken together, the results indicated NHERF to be a candidate tumor suppressor gene in human breast carcinoma that may be interconnected to the SYK and MERLIN suppressors.
Introduction
Like neoplasm of other sites, breast cancer undergoes multistep carcinogenesis that involves amplification or overexpression of oncogenes (such as AIB1, cyclin D1, ErbB2/Her2/neu, c-myc, and EGFR) and genetic or epigenetic alterations of tumor suppressor genes (such as p53, BRCA1, BRCA2, E-cadherin, and PTEN) that occurs in only a fraction of cases (Beckmann et al., 1997; Couch and Weber, 2002) . Many tumor suppressor genes are inactivated by intragenic mutations at one allele accompanied by loss of heterzygosity (LOH) at the other. In breast tumors, these molecular changes constantly interplay with hormonal changes and environmental factors (Lupulescu, 1993; Nandi et al., 1995) . Deregulation of the signaling pathways mediated by these gene products are believed to contribute to the pathobiology of breast cancer.
SYK (spleen tyrosine kinase) is a putative tumor or metastasis suppressor in mammary gland (Coopman et al., 2000; Yuan et al., 2001) . Loss or downregulation of SYK expression is associated with increased invasiveness (Coopman et al., 2000) and poorer prognosis of human breast cancinoma (Toyama et al., 2002) . Overexpression of SYK was shown to suppress mammary tumorigenicity (Coopman et al., 2000) , invasion (Coopman et al., 2000; Wang et al., 2003) , and motility (Mahabeleshwar and Kundu, 2003) . Although the SYK signaling pathway that mediates these biological responses in mammary epithelial cells remains undefined, the integrity of interdomain B (IDB) is indispensable for the invasion suppression activity of SYK (Wang et al., 2003) .
To understand the SYK signaling network and the critical role of IDB in the SYK biological functions, we used yeast two-hybrid screening to look for proteins that interact with the IDB of SYK. Here we describe the Na þ /H þ Exchanger Regulatory Factor (NHERF, also known as NHERF1 or EBP-50) gene whose protein product interacted with SYK. The finding of NHERF intragenic mutations implicates its role in breast tumor initiation or progression.
Results

Identification of a SYK interactor
We used yeast two-hybrid to search for proteins that interact with a putative mammary tumor suppressor, SYK. As it critically determines the invasion suppression activity of SYK (Wang et al., 2003) , the IDB was used as a 'bait' to screen a human breast tumor cDNA library. The screening yielded two cDNAs, one of which matched the human NHERF (#NM_004252). We verified the interaction of IDB and NHERF in yeast cells that had been pretransformed with the IDB cDNA. When cells were transformed with NHERF-containing plasmid, yeast outgrowth was observed on selection plates (Figure 1a, left panel) . In contrast, no cell survived when the control plasmid was used. All grown colonies expressed b-galactosidase (b-gal) (Figure 1a , right panel), indicating the physical interaction between NHERF and the IDB domain of SYK.
Confirmation of NHERF and SYK interaction
We used the glutathione-S-transferase (GST) pull-down assay to verify the interaction between NHERF and the IDB. NHERF contains two tandem PDZ domains (PDZDs) at its NH 2 -terminus that have been shown to interact with a variety of proteins (Hall et al., 1998; Wang et al., 1998; Mohler et al., 1999; Weinman et al., 2000) , and a MERLIN-binding motif at its COOHterminus. Wild-type PDZDs of NHERF were shown to bind to GST-IDB but not GST itself, confirming the physical binding of the two molecules ( Figure 1c) . However, the full-length NHERF was unable to bind to IDB (data not shown), suggesting an inhibitory effect at the COOH-terminus region.
Immunoprecipitation (IP)-immunoblotting (IB) analysis was also used to verify the interaction of NHERF and SYK in mammalian cells. COS7 cells were cotransfected with plasmids of HA-tagged NHERF and FLAG-tagged SYK. Lysates were subjected to IP (M2 FLAG antibody) and IB analyses (HA antibody). SYK was shown to co-immunoprecipate with NHERF, while an unrelated protein BAP (bovine alkaline phosphatase) was unable to bind to SYK (Figure 1d) . A positive NHERF-SYK interaction was observed when reverse IP (IP with HA and IB with M2) was used (data not shown). These results confirmed the presence and specificity of NHERF-SYK interaction in vivo. It also suggested that certain modifications of NHERF or relief of an inhibitory factor on the COOH-terminus is required for binding of PDZDs to SYK.
Mutational analyses of NHERF gene
Initial sequencing of the NHERF cDNA of the breast tumor cDNA library that was used for two-hybrid screening revealed a sequence variant (AAG to AAC) that would result in a switch of codon 172 (Lys-Asn). The mutation corresponded to a conserved basic residue in the second PDZD (Murthy et al., 1998) . We sought to verify this sequence variant at the genomic level. Using BLAST search, we found two clones (#AC016888 and #AC068874) that covered the six exons of the NHERF gene. We retrieved the tissue sections that contained both the tumor and its surrounding normal tissues from which DNAs were extracted. Polymerase chain reaction (PCR) amplification of exon 2 followed by direct sequencing confirmed the mutation at codon 172 ( Figure 2a) . Moreover, the mutation was somatic, since DNA from the surrounding normal tissue followed a wild-type sequence.
To validate NHERF as a tumor-suppressor gene, we evaluated a panel of breast cancer cell lines for LOH and intragenic mutations. The NHERF gene is mapped at 17q25, a region that undergoes frequent allelic loss in breast and ovarian cancer (Radford et al., 1995; Kalikin et al., 1996 Kalikin et al., , 1997 Plummer et al., 1997; Orsetti et al., 1999; Harkes et al., 2003) . LOH involving this locus was determined with three highly polymorphic markers (D17S785, D17S801, and D17S1351) that neighbored the NHERF gene. As defined in Materials and methods, 35 S]-labeled PDZDs of NHERF prepared by in vitro TNT reaction was mixed with GST-IDB attached to the beads. Bound PDZD proteins were eluted by boiling in SDS sample buffer, run on SDS-PAGE, and visualized by autoradiography. 10% of total input TNT lysate was run in parallel. (d) NHERF and SYK interact in vivo. pHA-NHERF was co-transfected with pFLAG-SYK or pFLAG-BAP (control) into COS7 cells. Cell lysates were subjected to IP-IB analyses as detailed in Materials and methods. Arrow and asterisk indicate precipitated NHERF and the heavy chain, respectively. This NHERF-SYK binding was reproduced in at least one independent experiment. IB using anti-FLAG and -HA antibodies was performed to verify the equivalent expression of tagged proteins (bottom two panels) presumptive LOH, in which single allele was present by all three markers, was inferred in 28 (58%) of the 48 breast cancer cell lines that we examined, namely BT20, BT474, BT549, CAMA1, HCC38, HCC1143, HCC1187, HCC1395, HCC1539, HCC2157, Hs578.T, Hs854.T, MB157, MCF7, MDA-MB-231, MDA-MB-415, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MDA-MB-468, MPE600, OCUB-F, SUM52PE, SUM149PT, SUM185PE, SUM1315M02, UACC812, and UACC893 ( Figure 3a , and data not shown). All coding sequences and splice junctions of the NHERF gene were then sequenced in all LOH-positive cases. Two cell lines, MDA-MB-231 and SUM149PT, were found to harbor mutations at exons 2 and 6, respectively. In MDA-MB-231, the mutation occurred at codon 180 (CGG-TGG) that predicted a missense mutation (Arg-Trp) corresponding to a conserved basic residue in the second PDZD ( Figure 2b ). In SUM149-PT, the mutation occurred at codon 301 (GAC-GTC; AspVal) that was located at the MERLIN-interacting motif ( Figure 2c ). The germline DNA for the two cell lines was not available to verify whether these mutations were truly somatic. To rule out the possibility that the two sequence variants represent genetic polymorphism, we evaluated 200 chromosomes from 100 unrelated individuals. Neither of the two sequence variants was identified in the germline DNAs. No silent mutation was found in the remaining cell lines. All these results suggested that the two intragenic mutations were likely associated with mammary neoplasia.
Mutations disrupt interactions with SYK and MERLIN
Mutations of a given tumor suppressor gene are predicted to disrupt its biologic activities. Using the GST pull-down assay, we first examined whether the tumorigenic mutations at the second PDZD (K172N and R180W) interfered with the SYK-PDZD physical interaction. Both mutants showed decreased binding to IDB (Figure 4a ), suggesting that the NHERF-SYK interaction may be associated with their tumor suppressor functions.
NHERF was previously reported to interact, through its COOH-terminus, with a family of ezrin-radixinmoesin membrane-cytoskeleton proteins (Reczek et al., 1997) . One of these is MERLIN, the product of neurofibromatosis 2 (NF2) tumor suppressor gene (Rouleau et al., 1993; Trofatter et al., 1993) . The effect of these tumorigenic mutations on NHERF binding to MERLIN was thus examined. As expected, mutation at COOH-terminus (D301V) abolished NHERF binding to MERLIN (Figure 4b ). Interestingly, a mutation at the PDZD (R180W) also affected NHERF-MERLIN interaction (Figure 4b ). This observation further suggested an intramolecular interaction between the NH 2 -and COOH-termini of NHERF.
LOH and mutation of NHERF gene in primary breast tumors
Next, we analysed our panel of 36 primary breast tumors for possible genetic alterations of NHERF, comparing them with corresponding neighboring normal tissues. LOH analyses indicated eight conclusive LOH cases that were confirmed by three markers (Figure 3b ), a rate (22%) that was lower than the one seen in cell lines (58%). This is likely due to the heterogeneity of the samples and their invariable contamination with normal DNA. Sequencing of all The clinical and pathologic parameters, including age of onset, tumor size, TNM stage, pathologic grading, and status of estrogen receptor a (ERa), progesterone receptor (PR), and Her2/neu expression, were reviewed for the 36 primary breast cancer cases. Statistical analyses indicated that LOH at the NHERF locus was strongly associated with the aggressive features of breast tumors. The LOH correlated with larger size, more advanced disease stage, and possibly higher grade ( Table 1 ). All of these associations predicted a poorer prognosis for tumors harboring LOH at the NHERF locus. Tumor-specific SYK gene promoter methylation has been found in a third of the breast carcinoma (Yuan et al., 2001) . When associating the LOH status with SYK methylation, an inverse correlation was observed (Table 1) .
Discussion
We have shown NHERF intragenic mutations in two breast cancer cell lines and one primary breast tumor that are accompanied by the loss of the second allele. In the primary tumor with available normal DNA, the mutation appeared to be somatic. The three mutations resulted in switches of highly conserved residues at the active domains, that is, two basic residues (K172N and R180W) at the second PDZD and one at the MERLINbinding domain (D301V). Both the genetic evidence and functional data support that NHERF is a candidate tumor suppressor gene that is targeted during breast tumor progression.
Combining results from cell lines (2/48) and primary tumors (1/37), the NHERF gene mutation had a rate of 3% (3/85). This relatively low rate is conceivably attributed to the heterogeneity of the disease. For example, BRCA1 and BRCA2 genes are involved in familial breast cancer but not in sporadic cases (Beckmann et al., 1997; Couch and Weber, 2002 ). An Labeled full-length NHERF and the corresponding tumorigenic mutants as indicated were mixed with GST or GST-MERLIN for pull-down analyses. Both D301V and R180W mutants interfered with NHERF binding to MERLIN, while K172N had no effect. Bound proteins were eluted, and analysed by SDS-PAGE and autoradiography. 10% of the total input of TNT lysate was run in parallel. All results have been reproduced in at least one independent experiment alternative interpretation of this low rate is that the signaling NHERF mediates is inactivated by mutagenesis of pathway's other components. Our results indicated that tumorigenic mutations of NHERF led to impaired interaction with at least one of the two tumor suppressors, MERLIN or SYK, suggesting that the three molecules probably belong to an integrated suppressor pathway in mammary gland. Both MERLIN and SYK are expressed in mammary epithelial cells (Rouleau et al., 1993; Arakawa et al., 1994; Coopman et al., 2000; Wang et al., 2003) . Genetic alteration of NF2 in breast tumors is infrequent (Arakawa et al., 1994; Bianchi et al., 1994; Yaegashi et al., 1995) , while inactivation of SYK through epigenetic mechanism occurs in a subset of cases (Yuan et al., 2001) . Our analyses showed that SYK methylation was inversely correlated with LOH at the NHERF locus (Table 1) . For a given tumor suppressive pathway, a mutually exclusive genetic (or epigenetic) inactivation would be expected for two critically required components, as exemplified by p53/MDM2 (Reifenberger et al., 1993) , Rb/p16/ CDK4 (Bartkova et al., 1996) , and APC/b-catenin (Morin et al., 1997) . Providing that LOH is a frequent event to inhibit NHERF signaling during mammary malignancy (see below), an inverse correlation of LOH and SYK methylation implicates a possible biological connection between SYK and NHERF, which is also suggested by the physical interaction between the two molecules. Further functional analyses of the NHERF signaling pathway are warranted to understand the NHERF suppression activity and its relation to other pathway components.
We have also shown that LOH at the NHERF locus is strongly associated with mammary malignancy. This prompts us to speculate that a compromised NHERF signaling may promote breast cancer initiation and progression by a haploinsufficiency mechanism (Kucherlapati et al., 2002; Magee et al., 2003; Srivastava et al., 2003; Staff et al., 2003) . This may also in part explain the relatively low rate of NHERF biallelic inactivation. Interestingly, the high LOH rate (58%) present in breast cell lines contrasts with a low incidence (B10%) in pancreatic and colorectal cancer cell lines examined (our unpublished data). Indeed, NHERF is an estrogen-inducible gene (Ediger et al., 1999; StemmerRachamimov et al., 2001) . In light of the critical roles of estrogen in the normal breast and ovary development and in the initiation and progression of breast and ovarian cancer, targeting of the NHERF locus may be a vital molecular change that leads to deregulated responses to hormonal signals. The suppressor role of NHERF and its induction by estrogen appears to contrast with the estrogen stimulatory effect on ERpositive breast cancer cells. To illustrate whether NHERF is a mediator or a negative feedback molecule of the estrogenic responses would predict the pathobiologic activity of NHERF in breast tumor progression. NHERF functions as an inhibitory factor for Na (Weinman et al., 2000 (Weinman et al., , 2003 . Augmented NHE3 activity through disturbed NHERF signaling could presumably assist tumor cell survival through accelerated elimination of intracellular H þ that are accumulated due to a combination of hypoxic microenvironment and an accelerated metabolic rate (Harris, 2002) . Tumor invasion and metastasis may also be promoted through activation of proteases by elevated extracellular [H þ ] (Stubbs et al., 2000) . These hypotheses remain to be tested.
Materials and methods
Cell lines and tissue samples
Breast cancer cell lines (BT20, BT474, BT483, BT549, CAMA1, DU4475, EVSA-T, HCC38, HCC1143, HCC1187, HCC1395, HCC1428, HCC1539, HCC1599, HCC1937, HCC2157, HCC2218, Hs578.T, Hs854.T, MB157, MCF7, MDA-MB-134IV, MDA-MB-175VII, MDA-MB-231, MDA-MB-330, MDA-MB-361, MDA-MB-415, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MDA-MB-468, MPE600, OCUB-F, SKBr5, SKBr7, SUM52PE, SUM102PT, SUM149PT, SUM159PT, SUM185PE, SUM225CWN, SUM229PE, SUM1315M02, T47D, UACC812, UACC893, ZR75-1, and ZR75-30) or their genomic DNAs were purchased from the American Type Culture Collection or supplied by Dr SP Ethier (University of Michigan), Dr E Stockert (SloanKettering Cancer Center), Dr H Smith (California Pacific Medical Center), and Dr N DeVleeschouwer (Institute Jules Bordet). Normal and neoplastic tissues were obtained from breast carcinomas resected at the MD Anderson Cancer Center and archived in the breast tumor bank. All normal and tumor samples were histologically verified. To screen for possible polymorphism at the NHERF exonic sequences, lymphocyte DNAs of a hundred randomly selected individuals were used. Slides of a breast tumor from which the cDNA library was made were purchased from Biochain (Hayward, CA, USA). Both the neoplastic and pathologically normal tissues were NHERF mutations in breast cancer JL Dai et al microdissected from the slides by laser capture prior to proteinase K digestion (see below).
DNA constructs
Full-length SYK cDNA was subcloned into pCMV6-FLAG vector (Sigma), generating pFLAG-SYK. NHERF cDNA was obtained by reverse transcription from mRNA of a breast cancer cell line, SKBr3, and amplified by PCR. Reverse transcriptase-PCR (RT-PCR) products were subcloned into a TA cloning vector (Invitrogen). NHERF cDNA was then subcloned into pCMV-HA vector (Clontech) and pcDNA3.1( þ ) (Invitrogen), generating pHA-NHERF and pDNA3.1-NHERF, respectively. To generate GST fusion, cDNA for the IDB of SYK (residue 261-370) was amplified by PCR and subcloned into pGEX2TK (Amersham Pharmacia). Similarly, NF2 cDNA (IMAGE clone from Research Genetics) was amplified by PCR and subcloned into pGEX2TK. Tumor-derived mutation sequences were introduced within the NHERF coding region of pcDNA3.1-NHERF by site-directed mutagenesis (Quick-change; Stratagene). All constructs generated by PCR were confirmed by automated sequencing.
Yeast two-hybrid screening
To identify SYK-interacting proteins, LexA-based yeast twohybrid screening (Hybrid Hunter system; Invitrogen) was performed in accordance with the manufacturer's protocol. To construct the bait vector pHybLex/Zeo-IDB, we subcloned IDB of SYK (residue 261-370) into EcoRI and KpnI sites of pHybLex/Zeo, a vector containing the LexA DNA-binding domain. Yeast strain EGY48/pSH18-34 was transformed with pHybLex/Zeo-IDB. The IDB-expressing yeast cells were then transformed with a cDNA library made from a human breast tumor (Invitrogen). Yeast colonies containing candidate interactors were selected by plating on -Trp-Uracil-Leu YC plates. The second marker, induction of b-gal expression, was confirmed by filter-lift assays. DNAs from positive yeast colonies were then extracted and propagated in Escherichia coli. The plasmid DNAs were then sequenced. The sequencing data were used for BLAST search of the NCBI cDNA database.
GST pull-down assays
GST pull-down assays were used to assess the interaction between NHERF and IDB or MERLIN. GST-IDB and GST-MERLIN were induced by isopropyl-b-D-1-thiogalactopyranoside (IPTG) in pGEX2TK-transformed BL21 strain and purified with glutathione-Sepharose beads. Radiolabeled fulllength or defined segments (PDZDs, residue 1-237) of NHERF were synthesized by in vitro transcription from pcDNA3.1 plasmids containing the NHERF cDNA and translated in the presence of [
35 S]-methionine (T7 Quick TNT kit, Promega). The translation products were mixed with purified GST-IDB or GST-MERLIN immobilized on the beads. Pull-down assays were performed at 41C for 1 h in 1 Â binding buffer (20 mM Tris (pH 7.5), 150 mM NaCl, and 1% NP-40). The beads were then washed thoroughly with 1 Â binding buffer. Bound proteins were eluted by boiling in 1 Â SDS sample buffer, separated by SDS-PAGE. 10% of the input TNT lysates were also run on the PAGE to determine the relative binding capacity. The PAGE gel was then dried and exposed for autoradiography.
Immunoprecipitation and immunoblotting
COS7 cells cultured in 100 mm dishes were co-transfected with pFLAG-SYK and pHA-NHERF by using FuGENE6 (Roche). To examine the specificity of the SYK-NHERF interaction, pFLAG-BAP was used to substitute pFLAG-SYK. One day following transfection, cells were harvested in 1 ml 1 Â lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, and 1 Â protease inhibitor cocktail (Sigma)). An aliquot of cell lysates was subjected to SDS-PAGE and IB, using antibodies against HA (Clontech) or FLAG (M2, Sigma). The remaining cell lysates were incubated overnight at 41C with 20 ml M2-conjugated agarose beads (Sigma). Beads were then collected and washed three times in 1 Â lysis buffer and eluted by boiling in 1 Â SDS sample buffer (without b-mercaptoethanol). Protein elutes were separated by SDS-PAGE and immuno-detected by anti-HA antibody (Clontech). Detection was afforded by horseradish peroxidase-conjugated secondary antibody and Supersignal reagents (Pierce).
LOH and mutational analyses of NHERF
The DNeasy kit (Qiagen) was used to extract genomic DNA from frozen tissues or cultured cells. LOH was determined using three highly polymorphic markers adjacent to the NHERF locus: D17S785, D17S801, and D17S1351 (from Research Genetics, heterozygosity indices provided by the manufacturer were 0.84, 0.86, and 0.78, respectively). In agreement, our LOH study using germline DNA of 36 unrelated individuals showed similar rates for the three markers (0.83, 0.75, and 0.83, respectively). LOH was conclusively present when analyses of the tumor DNA showed loss of one allele in comparison with its corresponding normal DNA. When normal genomic DNA was unavailable (cell lines), the LOH status was presumed by the unambiguous presence of a single allele size among all polymorphic markers evaluated. Based on their high heterzygosity ratios, the probability that a tumor cell line is homozygous for all three markers but does not have LOH at this region was o0.01. As expected, none of the 36 normal DNA samples showed homozygous at all three loci. PCRs for polymorphic markers were performed under the following conditions: 1.5 mM MgCl 2 , 2% DMSO, 200 mM dATP, dGTP, dTTP, 5 mM dCTP, 2 mCi [a-32 P]dCTP (3000 Ci/mmol, Perkin Elmer/NEN) in 1 Â PCR buffer (Invitrogen) with 250 nM PCR primers and 0.5 U Taq polymerase. In total, 40 ng of genomic DNA was amplified in a 10 ml reaction for 35 cycles (941C for 15 s, 551C for 30 s, and 721C for 30 s). The products were separated on a 6% acrylamide 8 M urea gel and subjected to autoradiography.
All six exons of the genomic DNAs from cell lines with conclusive LOH were selected for sequencing. Likewise, the six exons of the eight LOH-positive primary breast tumors were sequenced. Individual exon was amplified by PCR, using primers corresponding to the neighboring intronic sequences. Primers were: exon 1 (forward, 5 0 -tgggacacctgcttgcttg-3 0 ; reverse, 5 0 -atcctcctcccactccatg-3 0 ); exon 2 (forward, 5 0 -aattgctgt gtagggatctag-3 0 ; reverse, 5 0 -ggaagagagcgagaagcatc-3 0 ); exon 3 (forward, 3 0 -actgcaaactggctgagaac-3 0 ; reverse, 5 0 -tggctcacatccct gacttg-3 0 ); exon 4 (forward, 5 0 -attcatggtgggtggtagtc-3 0 ; reverse, 5 0 -caccttctgatctgtctcatg-3 0 ); exon 5 (forward, 5 0 -aggctcaggag gtgggaac-3 0 ; reverse, 5 0 -ggcttcctgtaacccagttg-3 0 ); and exon 6 (forward, 5 0 -agccgcattctgttcttgtg-3 0 ; reverse, 5 0 -gaaaaaggtggggt ggaatg-3 0 ). In total, 35 PCR cycles (30 s at 941C, 30 s at 641C, and 30 s at 721C) were carried out in a final volume of 30 ml that contained 67 mM Tris (pH 8.8), 16 mM (NH 4 ) 2 SO 4 , 10 mM b-mercaptoethanol, 1 mg/ml BSA, 4 mM MgCl 2 , 200 mM dNTP, 5% DMSO, 1 mM forward and reverse primers, and 0.5 U Taq polymerase in the presence of 40 ng genomic DNA. DNA extraction from microdissected samples was achieved by overnight digestion at 371C in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1% Tween-20, and 0.04% proteinase K. Proteinase K was subsequently inactivated at 951C for 8 min prior to PCR amplification. PCR products were purified by using QIAquick PCR purification kit (Qiagen) and subjected to automated sequencing (MD Anderson DNA Analysis Core Facilities). Mutations were confirmed by sequencing in reverse orientation on an independently amplified template. 
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